Security key
28617K101
Eledon Pharmaceuticals, Inc. - Common Stock (ELDN)
CUSIP: 28617K101
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 42,619,679
- Total 13F value
- $131,231,289
- Share change
- -1,745,248
- Put/Call ratio
- 0%
- SEC-reported price per share
- $3.08
- Number of holders
- 120
- Value change
- -$2,467,597
- Number of buys
- 71
- Number of sells
- 35
- Shares outstanding
- 77,196,950
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
120
Top holders
10
ELDN full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Eledon Pharmaceuticals, Inc. SEC filings
Eledon Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 28617K101
Recent filing periods:
Ownership snapshot
Top reported holders of ELDN - Eledon Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BIOTECHNOLOGY VALUE FUND L P
Disclosed value leader
BIOTECHNOLOGY VALUE FUND L P
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
13D/G row: BIOTECHNOLOGY VALUE FUND L P
Showing 1-6 of 15 holder rows.
Quick read
BIOTECHNOLOGY VALUE FUND L P leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BIOTECHNOLOGY VALUE FUND L P's linked filing trail.
Comparable ownership
Top 5
BIOTECHNOLOGY VALUE FUND L P
10%
BlackRock, Inc.
5.8%
ARMISTICE CAPITAL, LLC
5%
Coastlands Capital LP
5%
Frazier Life Sciences Public Fund...
2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
10%
|
$25,336,309
7,868,419 shares
|
$0 | 31 Mar 2026 |
| BlackRock, Inc. |
13D/G
13F
Company
|
5.8%
|
$13,493,040
4,380,857 shares
|
+$2,325,502 | 31 Mar 2026 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$10,259,798
3,137,553 shares
|
$0 | 31 Dec 2024 |
| Coastlands Capital LP |
13D/G
|
5%
|
$6,733,682
3,937,826 shares
|
-$1,410,519 | 31 Dec 2025 |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
James N. Topper
|
2%
|
$3,847,923
1,176,735 shares
|
$0 | 31 Dec 2024 |
| Keith Katkin |
3/4/5
Director
|
0.01%
|
$12,948
8,575 shares
|
— | 10 Jan 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
120
Shares
42,619,679
Rows available
120
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q1 2026 Across Filers
Q1 2026 holders
120
Q1 2026 holders
120
Holder diff
0
| Investor | Q1 2026 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend